Annovis Bio Statistics
Total Valuation
Annovis Bio has a market cap or net worth of $121.14 million. The enterprise value is $120.67 million.
Market Cap | 121.14M |
Enterprise Value | 120.67M |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024, after market close.
Earnings Date | Nov 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Annovis Bio has 13.05 million shares outstanding. The number of shares has increased by 22.09% in one year.
Shares Outstanding | 13.05M |
Shares Change (YoY) | +22.09% |
Shares Change (QoQ) | +4.46% |
Owned by Insiders (%) | 21.56% |
Owned by Institutions (%) | 7.55% |
Float | 10.24M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.24
Current Ratio | 1.24 |
Quick Ratio | 0.99 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -453.01% and return on invested capital (ROIC) is -269.05%.
Return on Equity (ROE) | -453.01% |
Return on Assets (ROA) | -183.39% |
Return on Capital (ROIC) | -269.05% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.69M |
Employee Count | 16 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.17% in the last 52 weeks. The beta is 1.72, so Annovis Bio's price volatility has been higher than the market average.
Beta (5Y) | 1.72 |
52-Week Price Change | +14.17% |
50-Day Moving Average | 8.60 |
200-Day Moving Average | 9.12 |
Relative Strength Index (RSI) | 54.36 |
Average Volume (20 Days) | 350,902 |
Short Selling Information
The latest short interest is 1.36 million, so 10.41% of the outstanding shares have been sold short.
Short Interest | 1.36M |
Short Previous Month | 1.20M |
Short % of Shares Out | 10.41% |
Short % of Float | 13.27% |
Short Ratio (days to cover) | 5.96 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -40.88M |
Pretax Income | -47.53M |
Net Income | -43.02M |
EBITDA | n/a |
EBIT | -40.88M |
Earnings Per Share (EPS) | -$5.26 |
Balance Sheet
Cash & Cash Equivalents | 4.00M |
Total Debt | n/a |
Net Cash | 4.00M |
Net Cash Per Share | $0.31 |
Equity (Book Value) | -1.75M |
Book Value Per Share | -0.15 |
Working Capital | 989,116 |
Cash Flow
Operating Cash Flow | -29.14M |
Capital Expenditures | n/a |
Free Cash Flow | -29.14M |
FCF Per Share | -$2.23 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Annovis Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.09% |
Shareholder Yield | -22.09% |
Earnings Yield | -34.51% |
FCF Yield | -23.38% |
Analyst Forecast
The average price target for Annovis Bio is $29.67, which is 219.72% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $29.67 |
Price Target Difference | 219.72% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |